Interstitial Lung Disease

Nintedanib slows the rate of forced vital capacity decline in patients with fibrosing autoimmune disease-related interstitial lung disease, with adverse events manageable for most, according to data published in Arthritis & Rheumatology.

One-fifth of patients with chronic medical conditions who received two doses of an mRNA COVID-19 vaccine had insufficient antibody levels at least 14 days after the second dose, researchers reported in Chest.

Heavy smoking, based on pack-years, in adults with progressive fibrosing interstitial lung disease was associated with increased risk for mortality, according to research published in Respiratory Medicine.

There is growing attention on the link between airways disease and rheumatoid arthritis.

More than 15% of patients with rheumatoid arthritis develop interstitial lung disease within 20 years, with the latter condition associated with shorter survival, according to data published in Arthritis Care & Research.

In a new study, concomitant medication burden was associated with antifibrotic medication intolerance in patients with idiopathic pulmonary fibrosis.

Longer travel distance to a subspecialty interstitial lung disease clinic was associated with worse clinical outcomes for patients with fibrotic ILD than those who live closer, researchers reported in Annals of the American Thoracic Society.

The Healio Editors compiled the most-read interstitial lung disease news published in 2021.

Rheumatoid arthritis-related mortality rates are declining, but death rates related to rheumatoid arthritis-interstitial lung disease remain stable for adults younger than 65 years, researchers reported.

In patients with rheumatoid arthritis-associated interstitial lung disease, more severe RA disease activity and impaired functional status were associated with increased mortality, according to data presented at ACR Convergence 2021.